| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7939502 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Jun, 2022
(1 year, 10 months ago) | |
| US6987094 | CHIESI | Optimized formulation of tobramycin for aerosolization |
Sep, 2022
(1 year, 6 months ago) | |
| US7696178 | CHIESI | Optimised formulation of tobramycin for aerosolization |
Sep, 2022
(1 year, 6 months ago) | |
Bethkis is owned by Chiesi.
Bethkis contains Tobramycin.
Bethkis has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Bethkis are:
- US7939502
- US6987094
- US7696178
Bethkis was authorised for market use on 12 October, 2012.
Bethkis is available in solution;inhalation dosage forms.
Bethkis can be used as management of cystic fibrosis patients.
The generics of Bethkis are possible to be released after 22 September, 2022.
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 12 October, 2012
Treatment: Management of cystic fibrosis patients
Dosage: SOLUTION;INHALATION
How can I launch a generic of BETHKIS before it's drug patent expiration?
More Information on Dosage
BETHKIS family patents
